Skip to Content
Merck
  • Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome.

Reduced dendritic arborization and hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome.

Brain : a journal of neurology (2014-04-22)
Christopher A Reid, Bryan Leaw, Kay L Richards, Robert Richardson, Verena Wimmer, Christiaan Yu, Elisa L Hill-Yardin, Holger Lerche, Ingrid E Scheffer, Samuel F Berkovic, Steven Petrou
ABSTRACT

Epileptic encephalopathies, including Dravet syndrome, are severe treatment-resistant epilepsies with developmental regression. We examined a mouse model based on a human β1 sodium channel subunit (Scn1b) mutation. Homozygous mutant mice shared phenotypic features and pharmaco-sensitivity with Dravet syndrome. Patch-clamp analysis showed that mutant subicular and layer 2/3 pyramidal neurons had increased action potential firing rates, presumably as a consequence of their increased input resistance. These changes were not seen in L5 or CA1 pyramidal neurons. This raised the concept of a regional seizure mechanism that was supported by data showing increased spontaneous synaptic activity in the subiculum but not CA1. Importantly, no changes in firing or synaptic properties of gamma-aminobutyric acidergic interneurons from mutant mice were observed, which is in contrast with Scn1a-based models of Dravet syndrome. Morphological analysis of subicular pyramidal neurons revealed reduced dendritic arborization. The antiepileptic drug retigabine, a K+ channel opener that reduces input resistance, dampened action potential firing and protected mutant mice from thermal seizures. These results suggest a novel mechanism of disease genesis in genetic epilepsy and demonstrate an effective mechanism-based treatment of the disease.

MATERIALS
Product Number
Brand
Product Description

Diazepam for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lamotrigine, ≥98%, powder
USP
Lamotrigine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Diazepam
Diazepam, European Pharmacopoeia (EP) Reference Standard
Supelco
Diazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material